Most coverage of brain–computer interfaces focuses on the moment a paralyzed patient moves a robotic arm. The less dramatic story — and the one that actually determines whether the technology reaches patients — is paperwork: who classifies the device, who pays for it, who is liable, and who protects the neural data.
In 2026, China wrote a great deal of that paperwork.
Key takeaways
- National priority: Brain–computer interfaces were included for the first time in China's Government Work Report in 2026, alongside future energy, quantum technology, embodied intelligence and 6G, as future industries to cultivate. BCI is also named in the 15th Five-Year Plan outline.
- Classification: The National Medical Products Administration issued Guiding Principles for the Classification and Definition of BCI Medical Devices; China's first industry standard for BCI medical devices has taken effect.
- Standards roadmap: On 24 August 2026, MIIT published a draft National BCI Industry Standard System Construction Guide (2026 edition): 40+ standards by 2028 (including lead/participation in 10+ international standards, with 100+ enterprises implementing them) and 80+ standards by 2030.
- Ethics first: Ethical guidelines for BCI research set out core principles including safeguarding health and advancing human wellbeing, and distinguish restorative from enhancement applications.
- Payment: Non-invasive BCI services have entered medical insurance reimbursement in Zhejiang and Beijing; Shanghai's "Hu Huibao" began covering BCI surgical consumables in May 2026; Guangdong added BCI services to its medical service price catalogue in June 2026.
- Market size: The China Center for Information Industry Development put China's BCI market at 3.2 billion yuan in 2024 (+18.8% year on year), projecting 5.58 billion yuan by 2027.
A seven-part architecture
The MIIT draft is the most concrete artefact. It organises BCI standardisation into seven parts: basic and common standards (terminology, reference architecture, testing and evaluation); hardware (electrodes, chips, modules, interfaces); software and algorithms (platforms, encoding/decoding algorithms, software interfaces); data and communication (formats, storage, transmission, fusion, visualisation); products and systems; industry applications; and safety and governance.
It also sorts BCI products into six categories — medical devices, industrial production, consumer electronics, personal health, scientific research, and converged applications — while stating plainly that anything meeting the definition of a medical device follows medical device law and standards.
Two features stand out. First, it brings consumer-grade neurotech inside the standards frame, which is unusual: regulators elsewhere are still deciding whether EEG headbands are wellness products or medical devices. Second, it runs safety and ethics through the entire structure rather than bolting them on — covering full-lifecycle risk control, software and hardware security, data security and privacy, and explicitly including informed consent, liability allocation and protection of vulnerable groups.
From implants to insurance codes
A device without a reimbursement pathway is a research project with a nice press release. China has been building that pathway alongside the technology:
- The National Healthcare Security Administration has established dedicated projects for BCI technology.
- Zhejiang and Beijing have brought non-invasive BCI-related medical services into insurance reimbursement.
- In May 2026, Shanghai's supplementary insurance programme Hu Huibao included BCI surgical self-pay consumables.
- In June 2026, Guangdong clarified BCI-related services as medical service price items.
This matters because most Chinese BCI companies are pursuing the non-invasive route — industry data suggests more than 80% of Chinese BCI enterprises work on non-invasive technology. Reimbursement for non-invasive therapy is therefore not a side detail; it is the commercial spine of the sector.
The unresolved questions
Chinese scholars are candid about what is not settled. Legal specialists have argued that neural data is fundamentally different from ordinary digital data because the rights involved are simultaneously personality rights and data rights, and have proposed regulatory sandboxes to generate practical experience before formal legislation — establishing rules for neural data privacy, data property rights and benefit allocation.
Researchers have also stressed that invasive BCI remains at the clinical trial stage and must rest on sufficient animal evidence, and that public understanding of BCI fundamentals, data rights and usage boundaries is still thin — producing both irrational fear and inflated expectations. The technical bottlenecks are equally real: highly biocompatible flexible electrodes, high-performance neural signal acquisition chips, and high-precision decoding algorithms all remain hard problems, and the long-term biological safety of invasive products needs larger and longer trials.
The direction, though, is clear. A sector that moved from "interesting lab result" to "national standard system with insurance codes" in roughly two years is a sector that intends to be an industry.
Based on MIIT, NMPA and National Healthcare Security Administration documents and Chinese media reporting in 2026. Standards marked above are targets set out in draft or published guidance.